Another small-scale study in NSCLC patients treated with nivolumab showed that higher ratios of systemic central memory and effector subsets in the total populations of CD4+ T cells was associated with immunotherapy benefit [19]. Here, CD4 is linked to non-small cell lung carcinoma.